Search

Displaying results 2831 - 2840 of 10000 in total
  1. Drug

    Steviolbioside

    go.drugbank.com/drugs/DB12434
    ApprovedWithdrawn

    Steviolbioside has been used in trials studying the treatment of HIV-1 Infection.

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    Fluvastatin

    go.drugbank.com/drugs/DB01095
    ApprovedInvestigational

    Fluvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. … HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis.

    Products: FLUVASTATIN AL 80MG RETARD, FLUVASTATIN 1A PH 80MG RET
  3. Drug

    Mephenesin

    go.drugbank.com/drugs/DB13583
    ApprovedWithdrawn

    Mephenesin is a synthetic cresol glyceryl ether which produces transient muscle relaxation and paralysis via central nervous system depression [A32760]. It first entered use in the 1950s.

  4. Drug

    Prednisolone acetate

    go.drugbank.com/drugs/DB15566
    ApprovedInvestigationalVet approved

    Prednisolone acetate is a [prednisolone] molecule bound to an acetate functional group by an ester bond.[L9449] Prednisolone acetate was granted FDA approval in 1955.[L9449]

  5. Drug

    Valganciclovir

    go.drugbank.com/drugs/DB01610
    ApprovedInvestigational

    As the L-valyl ester of ganciclovir, it is actually a prodrug for ganciclovir. After oral administration, it is rapidly converted to ganciclovir by intestinal and hepatic esterases. … Valganciclovir hydrochloride (Valcyte, manufactured by Roche) is an antiviral medication used to treat cytomegalovirus infections.

  6. Drug

    Mobocertinib

    go.drugbank.com/drugs/DB16390
    ApprovedInvestigationalWithdrawn

    It is used specifically in the treatment of non-small cell lung cancer (NSCLC) caused by exon 20 insertion mutations in the _EGFR_ gene,[L38368] which are typically associated with a poorer prognosis ( … Mobocertinib is a kinase inhibitor targeted against human epidermal growth factor receptor (EGFR).

  7. Drug

    Meningococcal polysaccharide vaccine group W-135

    go.drugbank.com/drugs/DB13887
    ApprovedInvestigational

    *N. meningitidis* is a bacteria that causes endemic and epidemic diseases including meningitis and meningococcemia. … It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup W-135.

    Mixtures: Menomune-A/c/y/w-135, Menomune-A/c/y/w-135Synonyms: Neisseria meningitidis group W-135 polysaccharide antigen, A
  8. Drug

    Methoxyflurane

    go.drugbank.com/drugs/DB01028
    ApprovedInvestigationalVet approvedWithdrawn

    If so employed, it should be administered with nitrous oxide to achieve a relatively light level of anesthesia, and a neuromuscular blocking agent given concurrently to obtain the desired degree of muscular … (From AMA Drug Evaluations Annual, 1994, p180) In the US, methoxyflurane is one of the products that have been withdrawn or removed from the market for reasons of safety or effectiveness.[L43942]

  9. Drug

    Olutasidenib

    go.drugbank.com/drugs/DB16267
    ApprovedInvestigational

    in 2-hydroxyglutarate (2-HG), a metabolite that participates in tumerogenesis. … Olutasidenib (FT-2102) is a selective and potent isocitrate dehydrogenase-1 (IDH1) inhibitor approved by the FDA in December 2022.

  10. Drug

    Toremifene

    go.drugbank.com/drugs/DB00539
    ApprovedInvestigational

    Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. … [A256928] Toremifene possesses tissue-specific actions: it has estrogenic (agonist) activity on the cardiovascular system and on bone tissue and it has weak estrogenic effects on uterine tissue, however